Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial

已完结 20 由天天发布于 2025/8/21 21:22:09

DOI:10.1016/s0140-6736(25)00866-9
作者：Fabrice Barlesi, Wenxiu Yao, Micha?l Duruisseaux, Ludovic Doucet, Aitor Azkárate Martínez, Vanesa Gregorc, Oscar Juan-Vidal, Shun Lu, Charlotte De Bondt, Filippo de Marinis, Helena Linardou, Young-C
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundAdagrasib is a KRASG12C inhibitor that demonstrated promising activity against KRASG12C-mutated advanced non-small-cell lung cancer (NSCLC) in a phase 2 trial. Here we aimed to com

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierCoengineering of Ni-NDC derived graphitic Ni2P/NiSe2 on a Ti3C2Tx MXene-modified 3D self-supporting electrode: Unraveling 2D?2D multiphases for overall water electrolysis